To carry out their activities, Research Teams of the Frédéric Joliot Institute for Life Sciences have developed high-profile technological platforms in many areas : biomedical imaging, structural biology, metabolomics, High-Throughput screening, level 3 microbiological safety laboratory...
All the news of the Institute of life sciences Frédéric Joliot
The “Clinical investigation” group consists of researchers, MDs, Pharmacists, highly involved in clinical research. Their goal is to design and test new imaging concepts for a better characterization of disease and for an enhanced understanding of the onset of disease, drug response and disease evolution over time, towards precision medicice. Their two main research areas are neurological diseases and cancer.
Team Leader: Nicolas Tournier
The Clinical Applications team builds upon the original molecular probes, imaging tools and methods developed by the other teams of the IMIV unit to propose, investigate and promote original clinical applications. The team is composed of physicians, radiopharmacists, pharmacologists, researchers, nurses and technicians specialized in nuclear medicine and clinical investigation. Members of the team strongly interact with some medical leaders in the neighborhood to provide new insights in the field of neuropsychiatric, cancer and pharmacology.
Fruitful collaborations prompt us to optimize the measurement of brain receptor occupancy and neurotransmission measurements using PET. These exams are improved in terms of patient comfort, dosimetry and PET data accuracy using a simultaneous PET-MRI system. This objective is a prerequisite to correlate regional cerebral PET signal with subsequent neuronal activation measured using functional MRI. Once optimized, PET-MRI protocols are used to elucidate the pharmacology of drugs that exhibit high variability in their clinical response in patients. The team has also great experience in the early diagnosis of Alzheimer's Disease and atypical forms of the disease using amyloid load measurement and alternative PET procedures.
Cancer imaging is a key research axis of the team project. The predictive value of innovative imaging procedures and PET radiopharmaceuticals is assessed in terms of prognostic and/or therapeutic response in selected patients with cancer. In this framework, combined PET-MRI provides complementary information about perfusion, cellularity and biological activity of the tumor. Pharmacological imaging studies are performed to image the distribution of anticancer drugs in tumors and healthy tissues in order to improve the comprehension of pharmacoresistance processes in patients.
Team Leader: Nicolas Tournier, CEA
Badia Ourkia Helal, MCU-PHMichel Bottlaender, IC CEAEsther Calvo-Bota, MN CEAAngèle Castilla-Lièvre, PH APHPFrancine Chassoux, PHSerge Desarnaud, MN CEAPhilippe Gervais, IC CEAClaire Leroy, IC CEAMichaël Soussan, MCU-PH APHPChristine Baron, IDE CEAChristine Boireau-Manciot, IDE CEAChristine Coulon, Tech CEASébastien Goutal, Tech CEAThierry Lekieffre, Tech CEASylvain Auvity, DoctViviane Brouilleret, PU PH
CEA is a French government-funded technological research organisation in four main areas: low-carbon energies, defense and security, information technologies and health technologies. A prominent player in the European Research Area, it is involved in setting up collaborative projects with many partners around the world.